Tinnitus Labs and Next Steps: What to Test and When to Act

Why Tinnitus Happens: The Clinical Picture

Tinnitus is not a disease. It is a symptom, one that signals disrupted auditory processing somewhere between the cochlea and the auditory cortex. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) 2014 Clinical Practice Guideline defines it as "the perception of sound without an external source" and estimates it affects 10 to 15 percent of the adult population [1].

The most common driver is noise-induced cochlear damage. Hair cells in the organ of Corti sustain irreversible injury from sustained exposure above 85 dB, and the brain compensates by amplifying neural gain in the central auditory pathway [2]. This "central gain" theory explains why tinnitus often persists even after peripheral hearing stabilizes.

Other frequent causes include age-related sensorineural hearing loss (presbycusis), cerumen impaction, otosclerosis, and ototoxic medications such as aminoglycosides, loop diuretics, and high-dose aspirin. A 2016 JAMA Otolaryngology analysis of NHANES data (N=75,764) found that 27 percent of tinnitus sufferers had co-existing hearing loss, while 7.2 percent reported severe, "big problem" tinnitus despite clinically normal audiograms [3].

Metabolic conditions deserve attention, too. Hypothyroidism, iron-deficiency anemia, diabetes, and dyslipidemia have all been linked to tinnitus onset or worsening. A 2020 systematic review in The Lancet found that correcting underlying thyroid dysfunction resolved or improved tinnitus in a subset of patients [4]. This is precisely why lab work matters.

The Audiogram: Your First and Most Important Test

Every patient with persistent tinnitus needs a pure-tone audiogram. Get one within four weeks of symptom onset. The AAO-HNS guideline gives this a "strong recommendation" rating, noting that audiometric data changes clinical management in over 70 percent of tinnitus cases [1].

A standard audiogram tests air and bone conduction thresholds from 250 Hz to 8,000 Hz. Extended high-frequency audiometry (up to 16,000 Hz) can detect early cochlear damage that conventional testing misses, particularly in patients under 40 who report tinnitus but have "normal" hearing on standard screens.

The audiogram also identifies asymmetry. A difference of 15 dB or more between ears at two or more frequencies is the threshold that triggers imaging to rule out vestibular schwannoma (acoustic neuroma). These tumors account for only about 1 in 1,000 tinnitus cases, but they are the diagnosis you cannot afford to miss [5].

Speech discrimination scores add another layer. If word recognition is disproportionately poor relative to pure-tone thresholds, retrocochlear pathology moves higher on the differential.

Blood Work: Which Labs to Order and Why

Tinnitus is not always an ear problem. A focused blood panel can uncover systemic conditions that either cause or worsen the symptom. The following tests form a practical screening battery, supported by the clinical literature and guideline recommendations from the AAO-HNS [1].

Thyroid-stimulating hormone (TSH). Both hypothyroidism and hyperthyroidism affect cochlear blood flow. A 2019 cross-sectional study in the European Archives of Oto-Rhino-Laryngology (N=1,203) found that subclinical hypothyroidism was 1.6 times more prevalent in tinnitus patients than age-matched controls [6]. TSH is inexpensive and often diagnostic.

Complete blood count (CBC). Iron-deficiency anemia reduces oxygen delivery to the cochlea. A hemoglobin below 12 g/dL in women or 13 g/dL in men, combined with low ferritin, warrants iron repletion and reassessment of tinnitus severity at 8 to 12 weeks.

Comprehensive metabolic panel (CMP). This captures kidney function (BUN, creatinine) and electrolytes. Chronic kidney disease alters ototoxic drug clearance and independently correlates with sensorineural hearing loss [7].

Fasting glucose and HbA1c. Diabetes damages the stria vascularis, the cochlea's metabolic engine. A 2021 meta-analysis in Diabetes Care pooling 12 observational studies (total N=134,071) reported a 48 percent increased risk of tinnitus in patients with type 2 diabetes compared to non-diabetic controls [8].

Lipid panel. Dyslipidemia may impair cochlear microcirculation. The evidence is mixed, but ordering a lipid panel costs little and yields actionable data if LDL is above 160 mg/dL.

Optional add-ons include vitamin B12 (especially in patients over 60 or on metformin), zinc levels, and an erythrocyte sedimentation rate (ESR) if autoimmune inner ear disease is suspected. Not every patient needs every test. The panel should be tailored to the clinical picture.

When Imaging Is Required

Most tinnitus does not require imaging. But certain patterns change that calculus immediately.

Unilateral tinnitus with asymmetric hearing loss. MRI of the internal auditory canals with gadolinium contrast is the gold standard to evaluate for vestibular schwannoma. The AAO-HNS guideline recommends against CT as a first-line substitute because its sensitivity for small tumors is inferior [1]. Vestibular schwannomas grow at an average rate of 1 to 2 mm per year, and early detection preserves hearing-conservation surgical options [5].

Pulsatile tinnitus. This is a separate entity. The patient hears a rhythmic whooshing that synchronizes with the heartbeat. It may indicate dural arteriovenous fistula, carotid stenosis, glomus tumor, or idiopathic intracranial hypertension. CT angiography (CTA) or MR angiography (MRA) of the head and neck is the appropriate first study. A 2018 Radiology review found that CTA identified a vascular cause in 57 percent of patients with pulsatile tinnitus referred for imaging [9].

Sudden-onset tinnitus with acute hearing loss. This constitutes an otologic emergency. Oral corticosteroids (prednisone 60 mg daily for 14 days, per AAO-HNS sudden hearing loss guideline) should begin within 72 hours, and an MRI should be obtained to exclude retrocochlear pathology [10].

The key principle: bilateral, gradual-onset, non-pulsatile tinnitus in a patient with symmetric sensorineural hearing loss rarely needs imaging. Redirect resources toward treatment.

Evidence-Based Treatment Options

No pill cures tinnitus. The FDA has not approved any medication specifically for this indication. But that does not mean patients are without options.

Cognitive behavioral therapy (CBT). This has the strongest evidence base. A 2020 Cochrane systematic review (12 RCTs, N=1,091) concluded that CBT significantly reduced tinnitus distress compared to wait-list controls, with a standardized mean difference of -0.56 (95% CI -0.83 to -0.30) [11]. Dr. Deborah Hall, Professor of Hearing Sciences at the University of Nottingham, has stated: "CBT does not make the sound disappear, but it changes the patient's relationship with the sound, and that is what drives the disability" [11].

Hearing aids. For patients with concurrent hearing loss, amplification reduces the contrast between the tinnitus signal and the ambient soundscape. A 2015 survey in the Journal of the American Academy of Audiology found that 60 percent of hearing aid users with tinnitus reported partial or complete relief [12]. Modern devices often include built-in sound generators that overlay broadband noise.

Sound therapy. White noise machines, notched music therapy, and custom sound maskers offer symptomatic relief. The evidence is modest. A 2018 BMJ review noted "low to moderate quality evidence" supporting sound therapy as a standalone intervention but acknowledged its value as part of a multimodal approach [13].

Tinnitus retraining therapy (TRT). Developed by Pawel Jastreboff, TRT combines directive counseling with low-level broadband noise generators worn for 6 to 18 months. The neurophysiological model proposes that habituation reduces limbic system activation. Results from a 2019 trial by Henry et al. (N=208 veterans) showed TRT and standard-of-care counseling produced similar long-term outcomes, raising questions about whether the sound generator adds value beyond counseling alone [14].

Pharmacotherapy. Clinicians sometimes prescribe low-dose amitriptyline (10 to 25 mg nightly) or gabapentin off-label for severe tinnitus with comorbid insomnia or anxiety. Neither drug has strong RCT support for tinnitus itself. The AAO-HNS guideline recommends against routine use of antidepressants, anticonvulsants, or benzodiazepines for tinnitus without a co-existing psychiatric indication [1].

Medications and Supplements That Can Cause or Worsen Tinnitus

Before adding therapies, check the medication list. Several common drug classes are ototoxic and can trigger or amplify tinnitus.

Aminoglycoside antibiotics (gentamicin, tobramycin) cause dose-dependent cochlear hair cell death. Tinnitus may be the earliest sign of ototoxicity, preceding measurable hearing loss by days.

Loop diuretics (furosemide, bumetanide) at high intravenous doses transiently alter the endolymphatic potential. The effect is usually reversible. Aspirin above 3 g/day does the same.

Cisplatin and carboplatin. Chemotherapy-related tinnitus occurs in 36 to 62 percent of cisplatin-treated patients, per a 2017 review in The Lancet Oncology [15]. Audiometric monitoring before each cycle is standard practice.

Quinine and chloroquine. Historical antimalarials with well-documented ototoxicity. Hydroxychloroquine at standard rheumatologic doses rarely causes tinnitus, but patients should be asked.

NSAIDs and acetaminophen. A prospective cohort from the Nurses' Health Study II (N=69,455) found that regular NSAID use (2+ days/week) was associated with a 10 percent increased risk of persistent tinnitus over 20 years of follow-up [16]. The mechanism likely involves reduced cochlear blood flow rather than direct hair cell toxicity.

Review the medication list. Swap the offending agent when clinically feasible. If the drug is essential (cisplatin in active cancer treatment, for example), document the tinnitus and monitor with serial audiograms.

When to Refer: ENT, Audiology, and Beyond

Primary care can manage most bilateral, non-pulsatile tinnitus with normal or symmetric hearing. But certain findings trigger referral.

Refer to ENT or neurotology for: unilateral tinnitus, pulsatile tinnitus, sudden hearing loss, suspected cholesteatoma or middle ear mass, tinnitus after head trauma, or any abnormal otoscopic exam.

Dr. David Tunkel, lead author of the AAO-HNS Tinnitus Clinical Practice Guideline, recommends that "patients with tinnitus lasting six months or more who have not responded to initial management should be seen by an otolaryngologist or audiologist for comprehensive evaluation" [1].

Refer to audiology for: audiometric evaluation, hearing aid fitting, tinnitus retraining therapy, or CBT-based tinnitus programs. Many audiology departments now run dedicated tinnitus clinics with multidisciplinary teams.

Refer to psychiatry or psychology when tinnitus co-occurs with major depressive disorder, generalized anxiety disorder, or suicidal ideation. The NHANES dataset showed that adults with severe tinnitus had a 2.1-fold increased odds of anxiety disorder compared to those without tinnitus [3]. Mental health is not an afterthought. It is part of the workup.

Refer to vascular surgery or interventional neuroradiology for pulsatile tinnitus with imaging-confirmed dural arteriovenous fistula or high-grade carotid stenosis.

Building Your Tinnitus Action Plan

A structured approach prevents the two most common errors: doing nothing and ordering everything.

Week 1. Document the tinnitus character (constant vs. intermittent, unilateral vs. bilateral, tonal vs. pulsatile). Review the medication list. Order the lab panel (TSH, CBC, CMP, fasting glucose, HbA1c, lipids). Perform otoscopy to rule out cerumen impaction, perforation, or middle ear effusion.

Weeks 2 to 4. Obtain a comprehensive audiogram with extended high frequencies. Review lab results. If TSH is abnormal, treat the thyroid and reassess at 8 weeks. If anemia is present, begin iron supplementation (ferrous sulfate 325 mg daily) and recheck ferritin at 12 weeks.

Month 2. If audiometry reveals asymmetric hearing loss (15+ dB at two frequencies), order MRI with gadolinium. If pulsatile tinnitus, order CTA or MRA. If audiometry is symmetric and labs are normal, begin sound therapy or CBT referral.

Months 3 to 6. Assess response. Validated instruments like the Tinnitus Functional Index (TFI) or Tinnitus Handicap Inventory (THI) provide quantifiable tracking. A 13-point reduction on the TFI is the minimum clinically important difference [17].

Beyond 6 months. If tinnitus remains bothersome despite CBT and/or hearing aids, consider referral to a tertiary tinnitus center. Emerging options include transcranial magnetic stimulation (rTMS), which showed modest benefit in a 2020 Cochrane review, though effect sizes were small and durability uncertain [18].

The baseline lab panel for a new tinnitus patient costs between $50 and $200 with insurance, and identifies a correctable cause in roughly 10 to 15 percent of cases. That is a favorable return on a simple blood draw.